

# PLENARY SESSION

Friday, April 28, 2023 | 4:30 – 5:30 pm

Co-Chairs: Ms. Judy Needham, Dr. Pierre-Olivier Gaudreau, Dr. Chris O'Callaghan, Dr. Wendy Parulekar



Dr. Marie Plante

4:30 – 4:45

**CX.5: SHAPE – A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early-Stage Cervical Cancer**

Dr. Marie Plante is a Professor in Obstetrics and Gynecology at Laval University. She was Vice-President of the International Gynecologic Cancer Society and is past Chair of the Cervical Cancer Research Network. Dr. Plante is interested in minimally invasive surgery, sentinel node mapping, and fertility-preserving surgery in cervical cancer.



Dr. Quincy Chu

4:45 – 5:00

**IND.227: A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma – Phase II Results**

Dr. Quincy Chu has extensive clinical research experience in novel therapeutics, thoracic malignancies, experimental therapeutics, and preclinical and translational research in the development of new cancer therapeutics. He is Chair of the CCTG Investigational New Drug Committee and member of the Lung Executive Committee. Dr. Chu is also co-lead of the Phase I Program and Thoracic Oncology Group at the Cross Cancer Institute in Calgary.



Dr. Stephen Welch

5:00 – 5:15

**ENC.1/NRG GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer**

Dr. Stephen Welch is an Associate Professor in the Department of Oncology at Western University, and Medical Oncologist, London Health Sciences Centre. He specializes in the treatment of gastrointestinal and gynecologic malignancies. Dr. Welch is the Co-Chair of the CCTG Gynecology Site Committee and is the President-Elect of the Canadian Association of Medical Oncologists.



Dr. Laura Dawson

5:15 – 5:30

**HE.1: Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases**

Dr. Laura Dawson is Professor and Chair of the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre. She is an internationally recognized leader in hepatobiliary cancer and in oligo-metastases.

